ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2382

Plasma Fibrinogen is an Accurate Marker of Disease Activity in Patients with Polymyalgia Rheumatica

E.M. McCarthy1, Paul A. MacMullan1, S. Al-Mudhaffer1, Anne M. Madigan1, S. Donnelly1, C. J. McCarthy1, Dermot Kenny2, Eamonn Molloy3 and G M. McCarthy1, 1Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, 2Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, 3Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: activity score and polymyalgia rheumatica, C-reactive protein (CRP)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Accurate determination of disease activity in polymyalgia rheumatica(PMR) is challenging due to the subjective nature of symptoms and concurrent musculoskeletal complaints in an elderly population.Any biomarker than assists physicians in more accurately determining patients disease state, thereby enabling safe adjustment of steroid dose would be welcomed. Previously we have demonstrated the enhanced specificity of plasma fibrinogen over both ESR and CRP for the detection of response to treatment in patients with active PMR. We sought to prospectively evaluate the utility of the biomarkers ESR, CRP and Fibrinogen for identifying different disease states in patients with known PMR.

Methods:

Patients with PMR were divided into high/moderate disease activity(Group 1) or low disease activity(Group 2) according to the Polymyalgia Rheumatica Activity Score(PMR-AS) as per Bird and Leeb. PMR-AS =CRP(mg/dl)+ VAS pain(0-10 scale)+ VASphysician (0-10scale)+Morning stiffness([min]x.1)+ Upper Limb Elevation(0-3 scale). A PMR-AS > 7 indicates medium/high disease activity with a PMR-AS < 7 indicating low disease activity. Plasma fibrinogen, CRP and ESR were also assayed. An ESR value of 30mm/hr(lab normal<20mm/hr) and CRP of 6mg/L (lab normal<5mg/l) were considered the upper limit for detection of low disease activity. The upper limit of the lab normal for Fibrinogen (4g/L) was used. Sensitivity, specificity, positive predictive values and likelihood ratios were calculated for all biomarkers.

Results: Data was available from 120 patient visits. Demographic data was similar in both groups. Mean age was 71.8 years. All patients were receiving glucocorticoids with a median steroid dose of 10mg in Group 1 and 5mg in Group 2.There were significant differences in steroid dose between the two groups(p<.001). 70 patients were defined as having low disease activity as per the PMR-AS.  Of these 64/70 had a normal plasma fibrinogen with 56/70 having an ESR <30mm/hr and 45/70 a CRP < 6mg/L. Table 1 shows the specificity, sensitivity, positive predictive values and likelihood ratios for the biomarkers as calculated for all 120 patient visits.

 

 

Specificity

Sensitivity

PPV

Likelihood Ratio

Fischers Exact Test

Fibrinogen

91%

52%

.81

6.06

P<.001

CRP

80%

90%

.66

2.68

P<.001

ESR

64%

50%

.64

2.5

P<.001

Overall plasma fibrinogen was more specific than either ESR or CRP for differentiating between low disease activity and moderate/high disease activity in PMR. It also demonstrated a better positive predictive value and likelihood ratio than the standard biomarkers ESR and CRP for identifying patients with moderate/high disease activity.

Conclusion:

Plasma fibrinogen can aid treating physicians in determining disease activity in PMR. An elevated plasma fibrinogen level more accurately indicates that patients are in a moderate or highly active disease state than either the ESR or CRP alone. Measurement of fibrinogen as an adjunct to ESR and CRP in patients with PMR can help treating physicians more accurately identify patients’ disease status and guide decisions with regards glucocorticoid dosage.


Disclosure:

E. M. McCarthy,
None;

P. A. MacMullan,
None;

S. Al-Mudhaffer,
None;

A. M. Madigan,
None;

S. Donnelly,
None;

C. J. McCarthy,
None;

D. Kenny,
None;

E. Molloy,
None;

G. M. McCarthy,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-fibrinogen-is-an-accurate-marker-of-disease-activity-in-patients-with-polymyalgia-rheumatica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology